Ann: Positive interim analysis of DMX-200 phase II data-DXB.AX, page-22

Stormer - its highly possible that Dimerix management may reach out to their US colleagues and industry peers/ contacts to let them know what they have discovered and share the results - then we may see some off shore interest from USA considering this is the "gateway" and market we are targeting hence the FDA meeting earlier - and when that happens im sure the US investors wont sit there sucking their thumbs once they find out - they can still call their international brokers and buy DXB

Given that 26 million CKD potential patients in the USA alone with Chronic Kindey disease , we are targeting a large audience and it will only grow due to poor dietary habits around the globe

tomorrow and the few days following could be VERY interesting once market has time to digest - as always time will tell

Cheers and GLTA
G101